Phase I

Arch Biopartners Inc., of Toronto


Peptide that blocks dipeptidase-1

Healthy volunteers (eventually inflammation, sepsis and cancer metastasis)

Started the single ascending dose arm of the 44-subject study to test the safety and pharmacokinetic profile of the drug; results expected later in 2019

Hutchison China Meditech Ltd., of London


Spleen tyrosine kinase inhibitor

Immune thrombocytopenia

First patient dosed in study testing the safety, tolerability, pharmacokinetics and preliminary efficacy of HMPL-523; the study, which will enroll 50-60 patients, includes a dose escalation stage and a dose expansion stage

Phase II

Beyondspring Inc., of New York


Sequesters tubulin heterodimers


In the phase II portion of the BPI-2358-105 study, the 20-mg/m2 dose over four treatment cycles improved patient reported quality of life measurements for global health status (p<0.0001), symptom scale (p<0.009), summary score (p<0.02), fatigue (p<0.03), pain (p<0.03) and insomnia (p<0.05)

Tenax Therapeutics Inc., of Morrisville, N.C.


Calcium sensitizer

Pulmonary hypertension and heart failure with preserved ejection fraction

The HELP study has enrolled 8 of 36 expected patients; 3 patients have completed the 6-week protocol and have rolled over to the 2-year extension study; study has 12 activated sites with 3 additional sites expected to be activated over the next few weeks; top-line data expected in the first quarter of 2020


For more information about individual companies and/or products, see Cortellis.


No Comments